Cyclophosphamide
Cyclophosphamide is an alkylating chemotherapy agent used to treat various cancers including lymphomas, leukemias, and solid tumors. It works by interfering with cancer cell DNA to stop their growth and division. This medication requires careful monitoring and is typically administered under the supervision of an oncologist.
An alkylating chemotherapy agent that damages cancer cell DNA to inhibit the growth of rapidly dividing malignant cells.
Key facts at a glance
- ATC
- L01AA01
- RxNorm
- 3002
- Generic
- Cyclophosphamide
- Class
- atc-l01
- Brands
- Frindovyx
- Availability
- rx
- Lactation
- unknown
- Routes
- oral
- Forms
- injection, solution, capsule, tablet
- Regions
- US, EU, CN, JP
- Monitoring
- —
This page is for informational purposes only.
Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.
Dosage and administration
- Usual dose
- 500mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 250mg twice daily
- Maximum
- consult physician
- Frequency
- every 12 hours
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
- Usual dose
- 400mg daily
- Maximum
- consult physician
- Frequency
- once daily
- Instructions
- Follow physician instructions
- Duration limits
- as prescribed
- Monitoring
- standard
Overdose information
Special Populations
9 groupspregnancy
first trimesteravoid if possible
avoid use during pregnancy unless benefits outweigh risks - known teratogenic effects
regular fetal monitoring, ultrasound assessments
Use of this medication in this population requires careful consideration of risks and benefits.
pregnancy
second third trimesteruse lowest effective dose
use only if benefits outweigh risks - monitor fetal growth closely
regular fetal monitoring, growth assessments
Use with caution and monitor for adverse effects.
lactation
nursingdiscontinue breastfeeding
do not breastfeed during treatment and for at least 1-2 weeks after last dose
monitor infant for signs of toxicity if exposure occurs
Use of this medication in this population requires careful consideration of risks and benefits.
pediatric_age
children 12 years and olderweight-based or body surface area dosing
use based on body surface area - monitor blood counts closely
frequent CBC monitoring, monitor for hemorrhagic cystitis
Use with caution and monitor for adverse effects.
geriatric
elderly 65 years and olderconsider dose reduction, start at lower end of dosing range
assess renal and hepatic function - adjust dose accordingly
close monitoring of renal function, blood counts, and fluid status
Use with caution and monitor for adverse effects.
renal_impairment
severe creatinine clearance below 30 ml minsignificant dose reduction required
reduce dose by 25-50% - consider alternative therapy
frequent monitoring of renal function and blood counts
Use of this medication in this population requires careful consideration of risks and benefits.
renal_impairment
moderate creatinine clearance 30 60 ml minmoderate dose reduction
reduce dose by 10-25% based on clinical response
regular monitoring of renal function and hematologic parameters
Use with caution and monitor for adverse effects.
hepatic_impairment
severeavoid or use with extreme caution
metabolized in liver - severe impairment increases toxicity risk significantly
frequent liver function tests and blood count monitoring
Use of this medication in this population requires careful consideration of risks and benefits.
hepatic_impairment
mild moderateconsider dose reduction
monitor liver function closely - adjust dose based on tolerance
regular liver function monitoring and blood counts
Use with caution and monitor for adverse effects.
Statistics and clinical data
FDA approval year
Original FDA approval date for Cyclophosphamide
Drug class
Pharmacological classification
Common uses
Primary therapeutic indications
Mechanism of action
Molecular mechanism of action
Treatment of various malignancies including Hodgkin's and non-Hodgkin's lymphomas, leukemias, multiple myeloma, neuroblastoma, retinoblastoma, and certain solid tumors. Also used as an immunosuppressant in some autoimmune conditions.
As an alkylating agent, cyclophosphamide produces active metabolites that cross-link tumor cell DNA, interfering with DNA replication and the growth of susceptible rapidly proliferating malignant cells.
Requires administration by healthcare professionals experienced in chemotherapy. Important safety considerations include adequate hydration to reduce bladder toxicity risk, regular monitoring of blood counts, and careful management of side effects such as bone marrow suppression, nausea, and hair loss.
Contraindications
Conditions and patient states where this medication should be avoided or used with caution.
Do not use (1)
Known allergy to this medication or its components
Use caution (1)
Consult healthcare provider for benefits vs risks assessment
Official drug label
WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.
This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy